{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"136-045-138-466-227","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"136-045-138-466-227"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11993,"type":"PATENT","title":"University of Connecticut Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3197,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8558,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Univ* Connecti*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2880
Search Applicants and Owners separately:Univ* Connecti*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2880
a. a purified interleukin-15 (IL-15) polypeptide and a purified soluble form of an interleukin-15 receptor alpha (IL-15Ra) polypeptide;\n
b. a purified chimeric polypeptide in which an IL-15 polypeptide is linked to a soluble form of an IL-15Ra polypeptide;\n
c. a purified IL-15 polypeptide and a purified chimeric polypeptide in which a soluble form of an IL-15Ra polypeptide is covalently linked to the Fc portion of an antibody;\n
d. a purified complex comprising an IL-15 polypeptide bound to a soluble form of an IL-15Ra polypeptide; or\n
e. a purified complex comprising an IL-15 polypeptide bound to a soluble form of an IL-15Ra polypeptide that is covalently linked to the Fc portion of an antibody,\nwherein said administration results in increasing proliferation of immune cells."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the composition is administered by a parenteral route."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the composition is administered by an intravenous route, subcutaneous route or intramuscular route."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the human has cancer, or the human has received a bone marrow or stem cell transplant."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the human is immunodeficient."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the human has AIDS."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the human is lymphopenic."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the effective amount increases proliferation of the immune cells as measured in an in vitro assay with CFSE-labeled immune cells, wherein CFSE dilution is measured by flow cytometry."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the composition comprises a purified IL-15 polypeptide and a purified soluble form of an IL-15Ra polypeptide."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the composition comprises a purified complex comprising an IL-15 polypeptide bound to a soluble form of an IL-15Ra polypeptide."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9 or 10, wherein the IL-15 polypeptide is:\n
(i) (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 2 over the entire length of SEQ ID NO: 2; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 6 over the length of the mature form of SEQ ID NO: 6; and\n
(ii) capable of forming a complex with IL-15Ra polypeptide."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9 or 10, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9 or 10, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the IL-15 polypeptide is:\n
(i) (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 2 over the entire length of SEQ ID NO: 2; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 6 over the length of the mature form of SEQ ID NO: 6; and\n
(ii) capable of forming a complex with IL-15Ra polypeptide."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO:8."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the IL-15 polypeptide has the amino acid sequence of SEQ ID NO:6."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 or 20, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO:8."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 23, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO:8."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A method for driving homeostatic proliferation of lymphokine responsive immune cells, comprising administering to a human an effective amount of a composition, wherein the composition comprises:\n
a. a purified interleukin-15 (IL-15) polypeptide and a purified soluble form of an interleukin-15 receptor alpha (IL-15Ra) polypeptide;\n
b. a purified chimeric polypeptide in which an IL-15 polypeptide is linked to a soluble form of an IL-15Ra polypeptide;\n
c. a purified IL-15 polypeptide and a purified chimeric polypeptide in which a soluble form of an IL-15Ra polypeptide is covalently linked to the Fc portion of an antibody;\n
d. a purified complex comprising an IL-15 polypeptide bound to a soluble form of an IL-15Ra polypeptide; or\n
e. a purified complex comprising an IL-15 polypeptide bound to a soluble form of an IL-15Ra polypeptide that is covalently linked to the Fc portion of an antibody,\nwherein said administration results in driving homeostatic proliferation of lymphokine responsive immune cells."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 25, wherein said purified IL-15 or said purified complex demonstrates an in vivo half-life of greater than an hour."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the composition is administered by a parenteral route."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the composition is administered by an intravenous route, subcutaneous route or intramuscular route."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the human has cancer, or the human has received a bone marrow or stem cell transplant."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the human is immunodeficient."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the human has AIDS."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 33, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO:8."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the IL-15 polypeptide has the amino acid sequence of SEQ ID NO:6."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 35, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 35 or 36, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO:8."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the IL-15 polypeptide is:\n
(i) (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 2 over the entire length of SEQ ID NO: 2; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 6 over the length of the mature form of SEQ ID NO: 6; and\n
(ii) capable of forming a complex with IL-15Ra polypeptide."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 38, wherein the soluble form of the IL-15Ra polypeptide is\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 38, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO:8."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the composition comprises a purified IL-15 polypeptide and a purified soluble form of an IL-15Ra polypeptide."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the composition comprises a purified complex comprising an IL-15 polypeptide bound to a soluble form of an IL-15Ra polypeptide."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 42 or 43, wherein the IL-15 polypeptide is:\n
(i) (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 2 over the entire length of SEQ ID NO: 2; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 6 over the length of the mature form of SEQ ID NO: 6; and\n
(ii) capable of forming a complex with IL-15Ra polypeptide."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 44, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 42 or 43, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 42 or 43, wherein the soluble form of the IL-15Ra polypeptide: (i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":47,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}